Ascentage Pharma Group International (NASDAQ:AAPG) Hits New 52-Week Low – What’s Next?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report)’s share price hit a new 52-week low during mid-day trading on Monday. The company traded as low as $13.43 and last traded at $13.43, with a volume of 10,087 shares trading hands. The stock had previously closed at $14.62.

Wall Street Analyst Weigh In

A number of research firms recently commented on AAPG. Citigroup began coverage on Ascentage Pharma Group International in a report on Wednesday, October 14th. They set a “buy” rating and a $46.00 target price for the company. Citizens Jmp started coverage on Ascentage Pharma Group International in a report on Tuesday, October 13th. They issued a “market outperform” rating and a $35.00 price objective on the stock. William Blair assumed coverage on Ascentage Pharma Group International in a report on Friday, October 16th. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. dropped their target price on shares of Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating for the company in a report on Thursday, October 8th. Finally, BTIG Research reissued a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Friday, August 21st. Two investment analysts have rated the stock with a Strong Buy rating and eleven have issued a Buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $43.44.

Get Our Latest Stock Analysis on AAPG

Ascentage Pharma Group International Trading Down 8.6%

The company has a debt-to-equity ratio of 1.09, a current ratio of 1.22 and a quick ratio of 1.18. The business has a fifty day moving average price of $15.36 and a 200 day moving average price of $19.61.

Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last posted its earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The firm had revenue of $22.24 million during the quarter. On average, research analysts expect that Ascentage Pharma Group International – Unsponsored ADR will post -2.43 earnings per share for the current year.

About Ascentage Pharma Group International

(Get Free Report)

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases. Its research focuses on therapies that target mechanisms involved in programmed cell death, or apoptosis, to help prevent cancer cells from surviving and multiplying. The company’s two approved oncology drugs in China are olverembatinib, used to treat certain forms of leukemia, and lisaftoclax (APG-2575), a BCL-2 inhibitor approved for certain patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Featured Articles

Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.